New results for severe influenza and inflammatory conditions

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Respiratory syncytial virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover in a week or two, but RSV can be serious, especially for infants and older adults. Prevent RSV Protect your child from

The role of artificial intelligence (AI) in therapeutic research has become increasingly prominent in recent years, with the potential to revolutionize drug discovery, testing, and personalized medicine. This transformative technology is poised to reshape the future of healthcare,

Artificial Intelligence (AI) and Machine Learning (ML) can be described as a branch of computer science, statistics, and engineering that uses algorithms or models to perform tasks and exhibit behaviors such as learning, making decisions, and making predictions.

The pharmaceutical industry is continually seeking novel approaches to create and identify effective treatments that cater to medical requirements. The procedure of discovering drugs is a daunting process that demands significant resources. Recently, this method has undergone significant

Artificial intelligence is revolutionising the pharmaceutical and biotechnology industries. Its unparalleled power to make predictions based on large data sets is advancing understanding of diseases, improving diagnostic speed and accuracy, accelerating drug discovery, and improving clinical trials. AI’s

Poolbeg Pharma plc has been granted a patent by the US Patent and Trademark Office (USPTO) for ways of treating hypercytokinaemia using a small molecule immunomodulator. The US patent covers the use of POLB 001 and related p38

The use of artificial intelligence (AI) in drug discovery is revolutionizing the pharmaceutical industry. AI-driven drug discovery has the potential to reduce the time and cost of drug development, while also improving the accuracy and efficacy of new treatments. However,

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Renowned futurist Ray Kurzweil has predicted a seismic shift in the balance of power between man and machine: a momentous occasion he calls “the singularity”. This prophecy foresees a time, likely to occur around 2045, when computers will

Health I see several ways in which AIs will improve health care and the medical field. For one thing, they’ll help health-care workers make the most of their time by taking care of certain tasks for them—things like

Poolbeg Pharma, an infectious disease firm spun out from Irish vaccine research company Open Orphan, has been granted a patent by the US Patent and Trademark Office (USPTO). The US patent is related to methods introduced by Poolbeg

Poolbeg Pharma has been granted a patent in the United States for the treatment of hypercytokinaemia using its new influenza drug POLB 001. The US patent covers the use of POLB 001 and related p38 MAP kinase inhibitors

Poolbeg Pharma has released new data from a human challenge trial that shows its treatment has strong potential in dampening inflammation in blood and tissues in influenza and other viral infections. POLB 001 showed success in reducing multiple markers